Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 11/2020

01-11-2020 | Affective Disorder | Original Paper

Lifetime Methamphetamine Use Disorder and Reported Sleep Quality in Adults Living with HIV

Authors: Ni Sun-Suslow, Rowan Saloner, Vanessa Serrano, Anya Umlauf, Erin E. Morgan, Ronald J. Ellis, Scott Letendre, Igor Grant, Robert K. Heaton

Published in: AIDS and Behavior | Issue 11/2020

Login to get access

Abstract

This study evaluated whether a history of lifetime methamphetamine (MA) use disorder increases risk for poor sleep quality in people with or without HIV infection (HIV+/HIV−). Participants (n = 313) were stratified into four groups based on HIV status and lifetime MA use disorder diagnosis [HIV+/MA+ (n = 84); HIV+/MA− (n = 141); HIV−/MA+ (n = 16); and HIV−/MA− (n = 72)] and compared on global sleep outcomes using the Pittsburgh Sleep Quality Index (PSQI). Significant differences on global sleep were observed between HIV+/MA+ and HIV+/MA− groups, but not between the HIV− groups. Follow-up multiple regression analyses within the HIV+ subgroups examined global sleep scores as a function of MA status and clinical covariates, including those related to HIV disease and demographics. HIV+ individuals with a history of MA use disorder evidenced significantly poorer sleep quality and were more likely to be classified as problematic sleepers than those without a lifetime disorder. This was independent of depressed mood, body mass index, and viral suppression while on treatment. Poorer reported sleep quality among HIV+/MA+ was associated also with multiple adverse functional outcomes, including greater objective cognitive impairment, unemployment, clinical ratings of functional impairment, and self-reported cognitive difficulties, decreased independence in activities of daily living, and poorer overall life quality. Interventions to avoid or curtail MA use in HIV+ individuals may help protect sleep quality and improve functioning.
Literature
1.
Clark JP III, Sampair CS, Kofuji P, Nath A, Ding JM. HIV protein, transactivator of transcription, alters circadian rhythms through the light entrainment pathway. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R656–R662662.PubMed
2.
Wu J, Wu H, Lu C, Guo L, Li P. Self-reported sleep disturbances in HIV-infected people: a meta-analysis of prevalence and moderators. Sleep Med. 2015;16(8):901–7.PubMed
3.
Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97–111.PubMed
4.
Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol. 2013;68(4):197–209.PubMedPubMedCentral
5.
Semple SJ, Patterson TL, Temoshok LR, McCutchan JA, Straits-Troster KA, Chandler JL, et al. Identification of psychobiological stressors among HIV-positive women. HIV Neurobehavioral Research Center (HNRC) Group. Women Health. 1993;20(4):15–36.PubMed
6.
Rondanelli M, Solerte SB, Fioravanti M, Scevola D, Locatelli M, Minoli L, et al. Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses. 1997;13(14):1243–9.PubMed
7.
Allavena C, Guimard T, Billaud E, De la Tullaye S, Reliquet V, Pineau S, et al. Prevalence and risk factors of sleep disturbance in a large hiv-infected adult population. Aids Behav. 2016;20(2):339–44.PubMed
8.
Passaro RC, Pandhare J, Qian HZ, Dash C. The complex interaction between methamphetamine abuse and HIV-1 pathogenesis. J Neuroimmune Pharmacol. 2015;10(3):477–86.PubMedPubMedCentral
9.
Bateganya M, Colfax G, Shafer LA, Kityo C, Mugyenyi P, Serwadda D, et al. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral-naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala. Uganda Aids Patient Care St. 2005;19(11):760–8.
10.
Passaro RC, Ramsey K, Segura ER, Lake JE, Reback CJ, Clark JL, et al. Speed kills: associations between methamphetamine use, HIV infection, tobacco use, and accelerated mortality among gay and bisexual men in Los Angeles, CA 20years after methamphetamine dependence treatment. Drug Alcohol Depen. 2019;195:164–9.
11.
Wang X, Ho WZ. Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission. Life Sci. 2011;88(21–22):972–9.PubMed
12.
Carrico AW, Flentje A, Kober K, Lee S, Hunt P, Riley ED, et al. Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. Brain Behav Immun. 2018;71:108–15.PubMedPubMedCentral
13.
Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I, et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003;188(12):1820–6.PubMed
14.
Fairbairn N, Kerr T, Milloy MJ, Zhang R, Montaner J, Wood E. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Behav. 2011;36(7):762–3.PubMedPubMedCentral
15.
Blackstone K, Iudicello JE, Morgan EE, Weber E, Moore DJ, Franklin DR, et al. Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med. 2013;7(4):255–63.PubMedPubMedCentral
16.
Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1–14.PubMed
17.
Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162(2):361–9.PubMedPubMedCentral
18.
Semple SJ, Patterson TL, Grant I. Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat. 2002;22(3):149–56.PubMed
19.
20.
London ED, Berman SM, Voytek B, Simon SL, Mandelkern MA, Monterosso J, et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry. 2005;58(10):770–8.PubMed
21.
London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61(1):73–84.PubMed
22.
Perez AY, Kirkpatrick MG, Gunderson EW, Marrone G, Silver R, Foltin RW, et al. Residual effects of intranasal methamphetamine on sleep, mood, and performance. Drug Alcohol Depend. 2008;94(1–3):258–62.PubMed
23.
Mahoney JJ III, De La Garza R, Jackson BJ II, Verrico CD, Ho A, Iqbal T, et al. The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res. 2014;219(2):367–71.PubMedPubMedCentral
24.
Tang J, Liao Y, He H, Deng Q, Zhang G, Qi C, et al. Sleeping problems in Chinese illicit drug dependent subjects. BMC Psychiatry. 2015;15:28.PubMedPubMedCentral
25.
Lago JA, Kosten TR. Stimulant withdrawal. Addiction. 1994;89(11):1477–81.PubMed
26.
Baberg HT, Nelesen RA, Dimsdale JE. Amphetamine use: return of an old scourge in a consultation psychiatry setting. Am J Psychiatry. 1996;153(6):789–93.PubMed
27.
Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. Aids Care. 2003;15(6):775–85.PubMed
28.
World Health Organization. Composite diagnositic international interview (CIDI, version 2.1). Geneva: World Health Organization; 1998.
29.
Beck A, Steer R, Brown G. Manual for beck depression inventory II (BDI-II). San Antonio: Psychology Corporation; 1996.
30.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–21313.PubMed
31.
Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(3):260–5.PubMed
32.
Putnins SI, Griffin ML, Fitzmaurice GM, Dodd DR, Weiss RD. Poor sleep at baseline predicts worse mood outcomes in patients with co-occurring bipolar disorder and substance dependence. J Clin Psychiatry. 2012;73(5):703–8.PubMedPubMedCentral
33.
Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–96.PubMedPubMedCentral
34.
Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded halstead reitan battery: demographically adjusted neuropsychological norms for African American and caucasian adults. Lutz: Psychological Assessment Resources, Inc; 2004.
35.
Heaton RK, Taylor MJ, Manly J. Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. Clinical interpretation of the WAIS-III and WMS-III. San Diego: Academic Press; 2003. p. 181–210.
36.
Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, Ake C, et al. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol. 2011;33(7):793–804.PubMedPubMedCentral
37.
Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 2012;26(6):894–908.PubMed
38.
Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10(3):317–31.PubMed
39.
Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I. HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology. 2008;22(1):110–7.PubMedPubMedCentral
40.
Chelune GJ, Heaton RK, Lehman RAW. Neuropsychological and personality correlates of patients' complaints of disability. Advances in clinical neuropsychology, vol 3. New York: Plenum Press; 1986. p. 95–126.
41.
Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46(4):M139–M144144.PubMed
42.
Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes. 2007;5:54.PubMedPubMedCentral
43.
Dustin DT, Kawachi I, Redline S. The social epidemiology of sleep. New York: Oxford University Press; 2019.
44.
Millar BM, Goedel WC, Duncan DT. Sleep health among sexual and gender minorities. Soc Epidemiol Sleep. 2019:187.
45.
Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2(4):194–9.PubMed
46.
Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med. 1994;56(1):8–17.PubMed
47.
Woods SP, Weber E, Weisz BM, Twamley EW, Grant I, Group HIVNRP. Prospective memory deficits are associated with unemployment in persons living with HIV infection. Rehabil Psychol. 2011;56(1):77–84.PubMedPubMedCentral
48.
Bhatia MS, Munjal S. Prevalence of depression in people living with HIV/aids undergoing art and factors associated with it. J Clin Diagn Res. 2014;8(10):1–4.
49.
50.
Jiao D, Liu Y, Li X, Liu J, Zhao M. The role of the GABA system in amphetamine-type stimulant use disorders. Front Cell Neurosci. 2015;9:162.PubMedPubMedCentral
51.
Padgett CL, Lalive AL, Tan KR, Terunuma M, Munoz MB, Pangalos MN, et al. Methamphetamine-evoked depression of GABA(B) receptor signaling in GABA neurons of the VTA. Neuron. 2012;73(5):978–89.PubMedPubMedCentral
52.
Kamata K, Kameyama T. Effect of chronic administration of methamphetamine on the responsiveness of substantia nigra zona reticulata neurons to GABA or a GABA agonist in rats. Naunyn Schmiedebergs Arch Pharmacol. 1986;334(4):458–62.PubMed
53.
Blumenfeld H. Neuroanatomy through clinical cases. 2nd ed. Sunderland: Sinauer Associates Inc.; 2012.
54.
Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publication; 2013.
55.
Downing MJ Jr, Houang ST, Scheinmann R, Yoon IS, Chiasson MA, Hirshfield S. Engagement in care, psychological distress, and resilience are associated with sleep quality among HIV-positive gay, bisexual, and other men who have sex with men. Sleep Health. 2016;2(4):322–9.PubMedPubMedCentral
56.
White JL, Darko DF, Brown SJ, Miller JC, Hayduk R, Kelly T, et al. Early central nervous system response to HIV infection: sleep distortion and cognitive-motor decrements. AIDS. 1995;9(9):1043–50.PubMed
57.
Norman SE, Chediak AD, Freeman C, Kiel M, Mendez A, Duncan R, et al. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep. 1992;15(2):150–5.PubMed
58.
Norman SE, Chediak AD, Kiel M, Cohn MA. Sleep disturbances in HIV-infected homosexual men. AIDS. 1990;4(8):775–81.PubMed
59.
Wiegand M, Moller AA, Schreiber W, Krieg JC, Fuchs D, Wachter H, et al. Nocturnal sleep EEG in patients with HIV infection. Eur Arch Psychiatry Clin Neurosci. 1991;240(3):153–8.PubMed
60.
Ferini-Strambi L, Oldani A, Tirloni G, Zucconi M, Castagna A, Lazzarin A, et al. Slow wave sleep and cyclic alternating pattern (CAP) in HIV-infected asymptomatic men. Sleep. 1995;18(6):446–50.PubMed
61.
Jean-Louis G, Weber KM, Aouizerat BE, Levine AM, Maki PM, Liu C, et al. Insomnia symptoms and HIV infection among participants in the Women's Interagency HIV Study. Sleep. 2012;35(1):131–7.PubMedPubMedCentral
62.
Lee KA, Gay C, Portillo CJ, Coggins T, Davis H, Pullinger CR, et al. Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. J Pain Sympt Manag. 2009;38(6):882–93.
63.
Weissman MM, Greenwald S, Niño-Murcia G, Dement WC. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry. 1997;19(4):245–50.PubMed
64.
Thomsen DK, Mehlsen MY, Christensen S, Zachariae R. Rumination—relationship with negative mood and sleep quality. Personality Individ Differ. 2003;34(7):1293–301.
65.
Heitkemper M, Jarrett M, Burr R, Cain K, Landis C, Lentz M, et al. Subjective and objective sleep indices in women with irritable bowel syndrome. Neurogastroenterol Motil. 2005;17(4):523–30.PubMed
66.
Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002;53(3):737–40.PubMed
67.
Gutierrez J, Tedaldi EM, Armon C, Patel V, Hart R, Buchacz K. Sleep disturbances in HIV-infected patients associated with depression and high risk of obstructive sleep apnea. SAGE Open Med. 2019;7:2050312119842268.PubMedPubMedCentral
68.
Palmer CA, Alfano CA. Sleep and emotion regulation: an organizing, integrative review. Sleep Med Rev. 2017;31:6–16.PubMed
69.
Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer's disease and cognitive decline in older persons. Sleep. 2013;36(7):1027–32.PubMedPubMedCentral
70.
O'Brien EM, Mindell JA. Sleep and risk-taking behavior in adolescents. Behav Sleep Med. 2005;3(3):113–33.PubMed
Metadata
Title
Lifetime Methamphetamine Use Disorder and Reported Sleep Quality in Adults Living with HIV
Authors
Ni Sun-Suslow
Rowan Saloner
Vanessa Serrano
Anya Umlauf
Erin E. Morgan
Ronald J. Ellis
Scott Letendre
Igor Grant
Robert K. Heaton
Publication date
01-11-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02857-7

Other articles of this Issue 11/2020

AIDS and Behavior 11/2020 Go to the issue

Notes From The Field

When Home is Not a Safe Place: Impacts of Social Distancing Directives on Women Living with HIV

Original Paper

Psychiatric Disorders and Substance Use Among African American Women in HIV Care

Original Paper

Using an HIV Self-test Kit to Test a Partner: Attitudes and Preferences Among High-Risk Populations

Original Paper

Retention in HIV Care Among HIV-Seropositive Pregnant and Postpartum Women in Uganda: Results of a Randomized Controlled Trial

Original Paper

Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming

Notes From the Field

Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits